Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded a decrease of -36.10%. However, over the last six months, the performance has been stronger by -50.21%. The price of KYTX increased 20.10% over the last 30 days. And in the last five days, it has surged by 3.02%.
Kyverna Therapeutics Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $17.06 on 06/13/24, while the lowest price for the same period was registered at $1.78 on 04/17/25.
52-week price history of KYTX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Kyverna Therapeutics Inc’s current trading price is -85.99% away from its 52-week high, while its distance from the 52-week low is 34.27%. The stock’s price range during this period has varied between$1.78 and $17.06. The Kyverna Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.0 million for the day, a figure considerably higher than their average daily volume of 0.27 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Kyverna Therapeutics Inc (KYTX) has experienced a quarterly decline of -17.30% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 103.29M and boasts a workforce of 112 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.70, with a change in price of -1.53. Similarly, Kyverna Therapeutics Inc recorded 319,909 in trading volume during the last 100 days, posting a change of -39.03%.
KYTX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for KYTX stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.01.
KYTX Stock Stochastic Average
As of today, Kyverna Therapeutics Inc’s raw stochastic average for the last 50 days stands at 70.11%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 94.02%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 69.79% and 67.16%, respectively.
